A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients …
JJ Vredenburgh, A Hussein, D Fisher… - Biology of Blood and …, 1998 - astctjournal.org
This study assessed the safety and efficacy of recombinant human interleukin (rhIL)-11 in
decreasing platelet transfusion requirements in patients with breast cancer who were
undergoing autologous bone marrow transplantation (ABMT) with peripheral blood
progenitor cell (PBPC) support. After high-dose therapy with cyclophosphamide, cisplatin,
and carmustine, 80 patients were randomized to one of three treatment groups: placebo
(26), 25 microg/kg of rhIL-11 (28), and 50 microg/kg of rhIL-11 (26). Of those randomized, 75 …
decreasing platelet transfusion requirements in patients with breast cancer who were
undergoing autologous bone marrow transplantation (ABMT) with peripheral blood
progenitor cell (PBPC) support. After high-dose therapy with cyclophosphamide, cisplatin,
and carmustine, 80 patients were randomized to one of three treatment groups: placebo
(26), 25 microg/kg of rhIL-11 (28), and 50 microg/kg of rhIL-11 (26). Of those randomized, 75 …